NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.
Saved in:
| Title: | NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. |
|---|---|
| Authors: | R Choo J; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Jeraj SN; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Sundar R; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Yong WP; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore., Lee M; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Huang Y; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Asokumaran Y; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Chan GHJ; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Ngoi NYL; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; NUS Centre for Cancer Research, National University of Singapore, Singapore, Singapore., Wong ALA; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Soo RA; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Chee CE; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Lim JSJ; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore., Goh BC; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore., Lee SC; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore., Tan DSP; Department of Haematology-Oncology, National University Health System, National University Cancer Institute, 1E Kent Ridge Road, National University Health System Tower Block Level 7, Singapore 119228, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2025 Jun 09; Vol. 17, pp. 17588359251339930. Date of Electronic Publication: 2025 Jun 09 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359251339930 |
